// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Predictors of Type 1 and Type 2 Myocardial Infarction

Ryan Wereski - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Cardiac Troponin Thresholds and Kinetics to Differentiate Myocardial Injury and Myocardial Infarction

Ryan Wereski - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Acute Coronary Syndromes

N/A

Stimulated Release of Apoptosis- Induced Endothelial Microparticles in Patients with Diabetes and Coronary Artery Disease

Isra Marei - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Telomerase Therapy Reverses Vascular Senescence and Extends Lifespan in Progeria Mice

Anahita Mojiri - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hutchinson-Gilford progeria syndrome

Prezatide copper acetate

Monocyte Subsets and Exercise Capacity in Patients With Atrial Fibrillation With Preserved Left Ventricular Function

farhan Shahid - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmia

Spironolactone

A Potential Therapeutic Antibody to Induce Collateral Formation in Cardiovascular Diseases

Jason Amartey - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Coronary Artery Disease

N/A

Amyloidogenic Medin Induces Endothelial Cell Prothrombotic Activation

Nina Karamanova - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Thrombomodulin alfa

The Bet Protein Inhibitor Apabetalone Rescues Diabetes Induced Impairment of Angiogenic Response

Shafeeq Ahmed A Mohammed - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Diabetes

Streptozotocin

A Novel Method of Conjunctival Vascular Screening to Detect Hemodynamic Alterations in Patients with Coronary Microvascular Disease

Jonathan A Mailey - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Angina

N/A

Phenotypic Drug Screen Reveals That Lacidipine, a Calcium Channel Blocker, Enhances the Vascular Lumen Formation

Dorota Nawrot - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Lacidipine

Genetic Enhancement of Epicardial Paracrine Signalling for Cardiac Regeneration

Liliana Brito - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Myocardial infarction

follistatin

Global Radial Strain Predicts Cardiovascular Events in Patients With Myocarditis Related to the Use of Immune Checkpoint Inhibitors

Thiago Silva - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Third-degree atrioventricular (AV) block

N/A

Global Circumferential Strain and Cardiovascular Events in Patients with Myocarditis Related to Immune Checkpoint Inhibitors

Thiago Q Silva - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Third-degree atrioventricular (AV) block

N/A

Dapagliflozin and Changes in Metabolic Syndrome in Patients With Type 2 Diabetes: A DECLARE TIMI 58 Sub-Analysis

Filipe A Moura - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Metabolic syndrome

Dapagliflozin

The Impact of Diabetes on Percutaneous Coronary Intervention Outcomes in STEMI Patients: The Asia-Pacific Evaluation of Cardiovascular Therapies (ASPECT) Collaboration

Mark Y Wong - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Venous thrombosis

N/A

Efficacy and Safety of Inclisiran by Baseline Glycemic Status: A Post Hoc Pooled Analysis of the ORION-10 and ORION-11 Phase III Randomized Controlled Trials

Lawrence A Leiter - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Diabetes

N/A

The Right Ventricle in Adolescent Athletes: Standing up for the Smaller Side

Sanjay Sivalokanathan - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arrhythmogenic right ventricular cardiomyopathy

N/A

Ertugliflozin Has Favorable Effects on Kidney Outcomes in Patients With Baseline Evidence of Heart Failure in VERTIS CV

David Cherney - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

Ertugliflozin

Cardiovascular, Metabolic and Safety Outcomes With Semaglutide by Age: A Post Hoc Analysis of SUSTAIN 6 and PIONEER 6

Mark Petrie - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Semaglutide

Differing Relations Of Arterial Stiffness And Carotid Intima-Media Thickness In Adolescence With Metabolic Risks In Young Adulthood: The ALSPAC Study

Andrew O Agbaje - American Heart Association (AHA) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Arterial stiffness

N/A

Copyright © 2026. QuantiNova All rights reserved